Do analysts prefer AVTE or ANTX?

Anthem has a consensus price target of $9.00, suggesting a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts plainly believe Anthem is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings & valuation, AVTE or ANTX?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is AVTE or ANTX more profitable?

Anthem's return on equity of -52.35% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Anthem N/A -52.35% -47.25%

Do analysts rate ANTX or ELYM?

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Anthem is more favorable than Eliem Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ANTX or ELYM?

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.10 N/A Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A

Is ANTX or ELYM more profitable?

Eliem Therapeutics' return on equity of -47.03% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -52.35% -47.25% Eliem Therapeutics N/A -47.03% -45.97%

Do analysts rate LWAC or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than LightWave Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LightWave Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, LWAC or ANTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LightWave Acquisition N/A N/A N/A N/A N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is LWAC or ANTX more profitable?

LightWave Acquisition's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets LightWave Acquisition N/A N/A N/A Anthem N/A -52.35% -47.25%

Do analysts rate SBTX or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, SBTX or ANTX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is SBTX or ANTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Anthem N/A -52.35% -47.25%

Does the media refer more to SBTX or ANTX?

In the previous week, Anthem had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Anthem and 1 mentions for Silverback Therapeutics. Anthem's average media sentiment score of -0.56 beat Silverback Therapeutics' score of -0.71 indicating that Anthem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silverback Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate NLTX or ANTX?

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts plainly believe Anthem is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Anthem 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, NLTX or ANTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Anthem N/A N/A -$35.17M -$1.10 N/A

Is NLTX or ANTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Anthem N/A -52.35% -47.25%

Anthem (ANTX) Competitors

$3.82 -0.35 (-8.39%)

Closing price 04:00 PM Eastern

Extended Trading

$3.81 -0.01 (-0.34%)

As of 07:56 PM Eastern

Compare

ANTX vs. AVTE, ELYM, LWAC, SBTX, and NLTX

Should you buy Anthem stock or one of its competitors? MarketBeat compares Anthem with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anthem include Aerovate Therapeutics (AVTE), Eliem Therapeutics (ELYM), LightWave Acquisition (LWAC), Silverback Therapeutics (SBTX), and Neoleukin Therapeutics (NLTX).

How does Anthem compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Anthem has a consensus price target of $9.00, suggesting a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts plainly believe Anthem is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Anthem has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market.

90.5% of Anthem shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 24.5% of Anthem shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anthem had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 beat Anthem's score of -0.56 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aerovate Therapeutics	Neutral
Anthem	Negative

Anthem's return on equity of -52.35% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Anthem	N/A	-52.35%	-47.25%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

Summary

Anthem beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Anthem compare to Eliem Therapeutics?

Anthem (NASDAQ:ANTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

Eliem Therapeutics' return on equity of -47.03% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-52.35%	-47.25%
Eliem Therapeutics	N/A	-47.03%	-45.97%

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher possible upside, equities research analysts clearly believe Anthem is more favorable than Eliem Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eliem Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

90.5% of Anthem shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 24.5% of Anthem shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A

In the previous week, Anthem had 3 more articles in the media than Eliem Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Anthem's score of -0.56 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anthem	Negative
Eliem Therapeutics	Neutral

Anthem has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the broader market.

Summary

Anthem beats Eliem Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Anthem compare to LightWave Acquisition?

LightWave Acquisition (NASDAQ:LWAC) and Anthem (NASDAQ:ANTX) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Anthem had 3 more articles in the media than LightWave Acquisition. MarketBeat recorded 3 mentions for Anthem and 0 mentions for LightWave Acquisition. LightWave Acquisition's average media sentiment score of 0.00 beat Anthem's score of -0.56 indicating that LightWave Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
LightWave Acquisition	Neutral
Anthem	Negative

90.5% of Anthem shares are owned by institutional investors. 24.5% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher possible upside, analysts plainly believe Anthem is more favorable than LightWave Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LightWave Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LightWave Acquisition	N/A	N/A	N/A	N/A	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

LightWave Acquisition's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LightWave Acquisition	N/A	N/A	N/A
Anthem	N/A	-52.35%	-47.25%

Summary

Anthem beats LightWave Acquisition on 6 of the 9 factors compared between the two stocks.

How does Anthem compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 24.5% of Anthem shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

In the previous week, Anthem had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Anthem and 1 mentions for Silverback Therapeutics. Anthem's average media sentiment score of -0.56 beat Silverback Therapeutics' score of -0.71 indicating that Anthem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silverback Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts clearly believe Anthem is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Silverback Therapeutics' return on equity of -29.62% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Anthem	N/A	-52.35%	-47.25%

Summary

Anthem beats Silverback Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Anthem compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Anthem (NASDAQ:ANTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 24.5% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Neoleukin Therapeutics' return on equity of -37.22% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Anthem	N/A	-52.35%	-47.25%

Anthem has a consensus price target of $9.00, indicating a potential upside of 135.60%. Given Anthem's stronger consensus rating and higher probable upside, analysts plainly believe Anthem is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

In the previous week, Anthem had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Anthem and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Anthem's score of -0.56 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Anthem	Negative

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Anthem	N/A	N/A	-$35.17M	-$1.10	N/A

Summary

Anthem beats Neoleukin Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$150.19M	$994.16M	$6.49B	$12.46B
Dividend Yield	N/A	4.84%	2.67%	5.34%
P/E Ratio	-3.47	1.49	23.93	23.64
Price / Sales	N/A	127.97	517.32	112.53
Price / Cash	N/A	20.06	42.35	57.17
Price / Book	1.97	7.92	9.73	6.37
Net Income	-$35.17M	-$4.04M	$3.56B	$337.36M
7 Day Performance	-11.78%	-2.79%	-3.19%	-3.07%
1 Month Performance	-18.55%	66.23%	-0.11%	0.37%
1 Year Performance	239.56%	110.65%	25.29%	27.87%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	2.9404 of 5 stars	$3.82 -8.4%	$9.00 +135.6%	+283.9%	$150.19M	N/A	N/A	N/A	News Coverage
AVTE Aerovate Therapeutics	N/A	$21.50 -1.0%	N/A	+142.6%	$623.18M	N/A	N/A	20	High Trading Volume
ELYM Eliem Therapeutics	N/A	$11.34 -5.2%	N/A	+709.3%	$337.39M	N/A	N/A	9
LWAC LightWave Acquisition	N/A	$10.20 flat	N/A	N/A	$306.82M	N/A	N/A	N/A	High Trading Volume
SBTX Silverback Therapeutics	N/A	$8.50 +4.0%	N/A	-39.8%	$306.49M	N/A	N/A	83	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. AVTE, ELYM, LWAC, SBTX, and NLTX

How does Anthem compare to Aerovate Therapeutics?

Summary

How does Anthem compare to Eliem Therapeutics?

Summary

How does Anthem compare to LightWave Acquisition?

Summary

How does Anthem compare to Silverback Therapeutics?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Summary

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. AVTE, ELYM, LWAC, SBTX, and NLTX

How does Anthem compare to Aerovate Therapeutics?

Do analysts prefer AVTE or ANTX?

Which has more volatility & risk, AVTE or ANTX?

Do institutionals & insiders have more ownership in AVTE or ANTX?

Does the media favor AVTE or ANTX?

Is AVTE or ANTX more profitable?

Which has preferable earnings & valuation, AVTE or ANTX?

Summary

How does Anthem compare to Eliem Therapeutics?

Is ANTX or ELYM more profitable?

Do analysts rate ANTX or ELYM?

Do institutionals and insiders hold more shares of ANTX or ELYM?

Which has stronger earnings and valuation, ANTX or ELYM?

Does the media favor ANTX or ELYM?

Which has more risk and volatility, ANTX or ELYM?

Summary

How does Anthem compare to LightWave Acquisition?

Does the media refer more to LWAC or ANTX?

Do institutionals & insiders believe in LWAC or ANTX?

Do analysts rate LWAC or ANTX?

Which has preferable valuation and earnings, LWAC or ANTX?

Is LWAC or ANTX more profitable?

Summary

How does Anthem compare to Silverback Therapeutics?

Which has more volatility & risk, SBTX or ANTX?

Do insiders and institutionals believe in SBTX or ANTX?

Which has preferable valuation and earnings, SBTX or ANTX?

Does the media refer more to SBTX or ANTX?

Do analysts rate SBTX or ANTX?

Is SBTX or ANTX more profitable?

Summary

How does Anthem compare to Neoleukin Therapeutics?

Do institutionals and insiders believe in NLTX or ANTX?

Is NLTX or ANTX more profitable?

Do analysts rate NLTX or ANTX?

Which has more risk & volatility, NLTX or ANTX?

Does the media favor NLTX or ANTX?

Which has stronger valuation and earnings, NLTX or ANTX?

Summary

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools